Ketorolac

NYU Langone Orthopedic Surgeons Present Latest Clinical Findings & Research at AAOS 2023

Retrieved on: 
Tuesday, March 7, 2023
NYU, MD, Elective surgery, Motion, Somnolence, American Academy, Orthopedic surgery, Dexamethasone, Pain management, Length, Length of stay, Nanotechnology, Patient, Notability, Surgeon, Research, AAOS, Rehabilitation, Fear, U.S. News & World Report, Injury, Nausea, News, Division, Learned helplessness, American Academy of Orthopaedic Surgeons, Ankle, Councillor, Faculty, Tissue, Analgesic, Bupivacaine, Anesthetic, Anxiety, Annual general meeting, NYU Langone Health, Walter, New York University Grossman School of Medicine, Synthetic control method, Hip fracture, William H. Harris (orthopaedic surgeon), Delirium, Ketorolac, Sleep, Nursing, Dentistry, Pharmaceutical industry, Pain, Foot

NEW YORK, March 7, 2023 /PRNewswire/ -- Experts from NYU Langone Orthopedics will present their latest clinical findings and research discoveries at the 2023 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, March 7 to 11, in Las Vegas.

Key Points: 
  • NEW YORK, March 7, 2023 /PRNewswire/ -- Experts from NYU Langone Orthopedics will present their latest clinical findings and research discoveries at the 2023 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, March 7 to 11, in Las Vegas.
  • 4 in the nation for orthopedics by U.S. News and World Report, performing more than 34,000 orthopedic procedures annually by more than 200 orthopedic physician faculty experts.
  • At this year's meeting, the faculty of NYU Langone Orthopedics will present 77 posters, 31 papers, 32 videos, and 38 symposia, courses, specialty programs, and special sessions.
  • "We have designed an opioid-sparing protocol at NYU Langone that aims to decrease narcotic use for total joint arthroplasty patients.

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Thursday, January 26, 2023
New Drug Application, Ibuprofen, LAS, United Kingdom, Fever, VAS, X-ray, Insomnia, Methoxyflurane, FDA, MRI, Hypoesthesia, Disease, IASP, Pain, Sufentanil, Trauma, Spasm, Paracetamol, Vertex, Patient, Depression, International Association, Medication, Weight loss, NDA, Abdominoplasty, MVP, International Association for the Study of Pain, Pregabalin, CT, Greatest Hits (Throbbing Gristle album), Fatigue, Inflammation, Ketorolac, VRS, Combustion, Chills, POC, Cough, Anxiety, Vertex Pharmaceuticals, TLC, Pharmaceutical industry, Dietary supplement, Poultry farming

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Thursday, January 26, 2023
New Drug Application, Ibuprofen, LAS, United Kingdom, Fever, VAS, X-ray, Insomnia, Methoxyflurane, FDA, MRI, Hypoesthesia, Disease, IASP, Pain, Sufentanil, Trauma, Spasm, Paracetamol, Vertex, Patient, Depression, International Association, Medication, Weight loss, NDA, Abdominoplasty, MVP, International Association for the Study of Pain, Pregabalin, CT, Greatest Hits (Throbbing Gristle album), Fatigue, Inflammation, Ketorolac, VRS, Combustion, Chills, POC, Cough, Anxiety, Vertex Pharmaceuticals, TLC, Pharmaceutical industry, Dietary supplement, Poultry farming

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market

Retrieved on: 
Tuesday, May 24, 2022
Science, Other Science, Research, Pharmaceutical, Alternative Medicine, Health, FDA, Other Health, USE, Hemostasis, RDY, Laboratory, Risk, History, NOT, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Ketorolac, Bleeding, RISK, Asthma, Automated Import Information System, Tris, Aspirin, Patient, Hives, Gastrointestinal bleeding, Kidney, Stomach, Myocardial infarction, Stroke, Human, Analgesic, Ulcerative colitis, CABG, NSE, IQVIA, Tablet, NSAID, Dan Senor, Extrapyramidal system, Pregnancy, Pain, Nonsteroidal anti-inflammatory drug, BSE, USFDA, Peptic ulcer disease, WITH, Possible Side Effects, NYSE, Perforation, CEO, Generic drug, Dietary supplement, Pharmaceutical industry, Birth control, Medical imaging, Phosphorus

Dr. Reddys Ketorolac Tromethamine Tablets USP, 10 mg, are available in bottle count sizes of 100.

Key Points: 
  • Dr. Reddys Ketorolac Tromethamine Tablets USP, 10 mg, are available in bottle count sizes of 100.
  • The total combined duration of use of ketorolac tromethamine tablets and ketorolac tromethamine should not exceed 5 days.
  • Ketorolac tromethamine tablets are not indicated for use in pediatric patients and they are NOT indicated for minor or chronic painful conditions.
  • Ketorolac tromethamine, including ketorolac tromethamine tablets can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal.

LayerBio Granted U.S. Patent for OcuRing™ Drug Delivery Platform

Retrieved on: 
Wednesday, December 1, 2021
Patient, Patent, CEO, Ophthalmology, Nonsteroidal anti-inflammatory drug, USPTO, Compliance, Ketorolac, Inflammation, Founder, Therapy, Eye, Pain, NSAID, GLOBE, Board of directors, Board, Doctor of Philosophy, Method, Pharmaceutical industry, Veterinary medicine

LEXINGTON, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- LayerBio, Inc. (LayerBio), an ophthalmology therapeutics company, announced todaythat the United States Patent and Trademark Office (USPTO) has issued US Patent No.

Key Points: 
  • LEXINGTON, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- LayerBio, Inc. (LayerBio), an ophthalmology therapeutics company, announced todaythat the United States Patent and Trademark Office (USPTO) has issued US Patent No.
  • "This patent issuance marks an important milestone for the OcuRingplatform and recognition of novelty and uniqueness of our drug delivery technology," said Kenneth Mandell, M.D.,Ph.D., CEO and Founder of LayerBio.
  • The patent provides coverage for a variety of drug product compositions, methods of use, and delivery systems for LayerBio's proprietybioerodible drug delivery ringsthat release therapeutic medications for use in cataract surgery.
  • "By automatically releasing medicine inside the eye after cataract surgery, OcuRing can ensure compliance,improveoutcomes and enhancethe overall patient experience."

Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference

Retrieved on: 
Wednesday, June 9, 2021
Biotechnology, General Health, Pharmaceutical, Health, Drugs, Medical specialties, Vasoconstrictors, Nonsteroidal anti-inflammatory drugs, Ophthalmology, Organ systems, Amines, Phenylephrine, Ketorolac, Omero

Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week.
  • The fireside chat with Bank of America analyst, Geoff Meacham, PhD, is scheduled for Tuesday, June 15, 2021 at 4:30 p.m. EDT.
  • Its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery.
  • One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors.

Nephron Announces FDA Approval of Ketorolac, Signaling New Phase of Growth

Retrieved on: 
Tuesday, December 22, 2020
Drugs, Psychoactive drugs, Neurochemistry, Amines, Analgesics, Ketorolac, Ophthalmology, Syntex, Tris, Generic drug, Abbreviated New Drug Application, Ketamine

The company today announced Food and Drug Administration (FDA) approval of the Nephron Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 60 mg/2 mL (30 mg/mL) in Single-Dose Vials.

Key Points: 
  • The company today announced Food and Drug Administration (FDA) approval of the Nephron Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 60 mg/2 mL (30 mg/mL) in Single-Dose Vials.
  • Ketorolac Tromethamine becomes one of the first ANDA-approved non-respiratory generic medications produced by Nephron, signaling a new phase of company growth.
  • Nephron secured FDA approval for Sodium Chloride IV Bags earlier this year.
  • "We are extraordinarily excited to expand our generic medication portfolio to include non-respiratory products," said Nephron CEO Lou Kennedy.

CMS Confirms Continued Separate Payment for Omeros’ FDA-Approved OMIDRIA® in Ambulatory Surgery Centers

Retrieved on: 
Thursday, December 3, 2020
Biotechnology, Pharmaceutical, Optical, Health, Medical specialties, Health care, Drugs, Nonsteroidal anti-inflammatory drugs, Ophthalmology, Vasoconstrictors, Federal assistance in the United States, Healthcare reform in the United States, Outpatient surgery, Phenylephrine/ketorolac, Medicare, Ketorolac, OMIDRIA®, Omeros Corporation

Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros cataract surgery drug OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros cataract surgery drug OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%.
  • In its final rule directed to the Medicare outpatient prospective payment system (OPPS) and the ASC payment system for calendar year 2021, CMS confirmed that OMIDRIA qualifies for separate payment under CMS policy for non-opioid pain management surgical drugs when used in the ASC setting.
  • Omeros appreciates CMS decision to continue paying separately for our ophthalmic drug OMIDRIA, said Gregory A. Demopulos, M.D., Omeros chairman and chief executive officer.
  • Having just come off its pass-through status, this is the first time that OMIDRIA qualifies under CMS payment policy for non-opioid pain-management surgical drugs in the ASC setting.

Oculis announces presentation of positive results from Phase 2 trial of OCS-01 in patients with Diabetic Macular Edema (DME) at EURETINA 2020 Virtual

Retrieved on: 
Monday, October 5, 2020
Organ systems, RTT, Clinical medicine, Medicine, Ophthalmology, Diabetes, Organofluorides, Macular edema, Diabetic retinopathy, Dexamethasone, Ketorolac

OCS-01 is a novel, high concentration, topical formulation of dexamethasone (ophthalmic suspension 1.5%) developed using Oculis proprietary Soluble NanoParticle technology (SNP).

Key Points: 
  • OCS-01 is a novel, high concentration, topical formulation of dexamethasone (ophthalmic suspension 1.5%) developed using Oculis proprietary Soluble NanoParticle technology (SNP).
  • The DX-211 study was a prospective, multi-center, randomized, double-masked, parallel group, vehicle-controlled Phase 2 study.
  • OCS-01 is moving to Phase 3 in two indications Diabetic Macular Edema (DME) and post-ocular surgery following a positive End-of-Phase 2 meeting with FDA.
  • Oculis has an experienced management team from global ophthalmic companies and is supported by leading international life science investors.

Omeros Provides Update on Separate Payment for OMIDRIA® in the ASCs

Retrieved on: 
Thursday, October 1, 2020
Public policy, Government, Insurance, Pharmaceutical, Optical, General Health, Health, Other Policy Issues, Professional services, Medical specialties, Drugs, Clinical medicine, Nonsteroidal anti-inflammatory drugs, Ophthalmology, Vasoconstrictors, RTT, Healthcare in the United States, Prospective payment system, Medicare, Phenylephrine/ketorolac, Ketorolac, Omeros Corporation, OMIDRIA®

Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3% .

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3% .
  • The two-year extension of pass-through status provided by Congress through the Consolidated Appropriations Act of 2018 for OMIDRIA expired today.
  • CMS policy for separate payment applies to non-opioid pain management surgical drugs that are used in the ASC setting and that are policy-packaged under CMS Outpatient Prospective Payment System.
  • If enacted, the bill would provide separate Medicare reimbursement for non-opioid treatments to manage pain, like OMIDRIA, in both ASCs and hospital outpatient departments, renewable every five years.